Dendritic cell-based therapeutic vaccination for acute myeloid leukemia
Bulletin du Cancer, 06/22/2012
Anguille S et al. – The eradication of MRD, with the eventual aim of reducing the risk of relapse, therefore represents a high–priority goal of modern acute myeloid leukemia (AML) therapy. It is now well established that the immune system plays a crucial role in the defense against AML. This knowledge has fuelled the development of immune–based approaches to control MRD and, ultimately, to prevent relapse. One of the promising strategies that have emerged in this regard involves the use of dendritic cells for therapeutic vaccination.